Artemether

Moderate

Artemether Acetaminophen And Codeine Capital® & Codeine Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Clindamycin ANTIROBE Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Omeprazole Gastrobim Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Colchicine Colcrys Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Simvastatin Flolipid Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Abemaciclib Verzenio Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Acalabrutinib Calquence Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Alpelisib Piqray Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Apixaban Eliquis Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Apremilast Otezla Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Atogepant Qulipta Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Avapritinib Ayvakit Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Avatrombopag Doptelet Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Bicalutamide Casodex Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Artemether Cariprazine Vraylar Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Abiraterone Abirtega Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Avanafil Stendra Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Axitinib Inlyta Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Bexarotene Targretin Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy Details Artemether Bexarotene Topical Targretin Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy Details Artemether Bosutinib Bosulif Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Brexpiprazole Rexulti Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Brivaracetam Briviact Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy Details Artemether Brivaracetam Injection Briviact Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy Details Artemether Brodalumab Injection Siliq Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Artemether Budesonide Entocort Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Budesonide Nasal Spray Rhinocort Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Budesonide Oral Inhalation Pulmicort Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Cabozantinib Cabometyx Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Cabozantinib (Thyroid Cancer) Cabometyx Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Capmatinib Tabrecta Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Clindamycin Injection ANTIROBE Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Clindamycin Topical C/T/S® Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Clindamycin Vaginal Cleocin Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Clotrimazole Aardora Anti-Fungal Maximum Strength Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Artemether Clotrimazole Lozenge Mycelex® Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Artemether Clotrimazole Topical Cruex Antifungal Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Artemether Clotrimazole Vaginal Gyne-Lotrimin 3® Cream Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Artemether Cobimetinib Cotellic Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Artemether Deflazacort Emflaza Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details